CY1122531T1 - Νεα χρηση - Google Patents

Νεα χρηση

Info

Publication number
CY1122531T1
CY1122531T1 CY20201100075T CY201100075T CY1122531T1 CY 1122531 T1 CY1122531 T1 CY 1122531T1 CY 20201100075 T CY20201100075 T CY 20201100075T CY 201100075 T CY201100075 T CY 201100075T CY 1122531 T1 CY1122531 T1 CY 1122531T1
Authority
CY
Cyprus
Prior art keywords
nepi
effective amount
angiotensin receptor
patient
inhibitor
Prior art date
Application number
CY20201100075T
Other languages
English (en)
Inventor
Victor Chengwei Shi
Martin Lefkowitz
Adel Remond RIZKALA
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122531(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1122531T1 publication Critical patent/CY1122531T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μεθόδους και φαρμακευτικές συνθέσεις για την πρόληψη ή την καθυστέρηση του χρόνου μέχρι την πρώτη εμφάνιση θνησιμότητας, συγκεκριμένα καρδιαγγειακού θανάτου, ή/και καρδιαγγειακών νοσηλειών σε έναν ασθενή που πάσχει από χρόνια συστολική καρδιακή ανεπάρκεια, οι οποίες περιλαμβάνουν χορήγηση μιας θεραπευτικούς αποτελεσματικής ποσότητας, ή μιας προφυλακτικώς αποτελεσματικής ποσότητας, ενός αναστολέα Υποδοχέα Αγγειοτενσίνης Νεπριλυσίνη (ΑRΝi) ή ενός συνδυασμού Δεσμευτή Υποδοχέα Αγγειοτενσίνης (ΑRΒ) με έναν αναστολέα Ουδέτερης Ενδοπεπτιδάσης (ΝΕΡi) ή με ένα προφάρμακο ΝΕΡi στον εν λόγω ασθενή.
CY20201100075T 2013-08-26 2020-01-28 Νεα χρηση CY1122531T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31
PCT/IB2014/064074 WO2015028941A1 (en) 2013-08-26 2014-08-26 New use

Publications (1)

Publication Number Publication Date
CY1122531T1 true CY1122531T1 (el) 2021-01-27

Family

ID=51494327

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100075T CY1122531T1 (el) 2013-08-26 2020-01-28 Νεα χρηση

Country Status (15)

Country Link
US (2) US20160213646A1 (el)
EP (3) EP3626270B1 (el)
JP (1) JP6097888B2 (el)
CY (1) CY1122531T1 (el)
DK (2) DK3626270T3 (el)
ES (2) ES2968541T3 (el)
FI (1) FI3626270T3 (el)
HR (2) HRP20240034T1 (el)
HU (2) HUE064634T2 (el)
LT (2) LT3038654T (el)
PL (2) PL3038654T3 (el)
PT (2) PT3038654T (el)
RS (2) RS59816B1 (el)
SI (2) SI3626270T1 (el)
WO (1) WO2015028941A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016125123A1 (en) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
US20180140579A1 (en) * 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
WO2017063581A1 (zh) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
US20190054069A1 (en) 2016-02-03 2019-02-21 Novartis Ag New use of a combination of sacubitril and valsartan
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2021052441A1 (zh) * 2019-09-20 2021-03-25 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0443983T3 (da) 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
IL130599A0 (en) * 1997-01-10 2000-06-01 Merck & Co Inc Use of angiotensin II antagonists to treat symptomatic heart failure
CN1615134A (zh) 2002-01-17 2005-05-11 诺瓦提斯公司 含有缬沙坦和nep抑制剂的药物组合物
MXPA05012299A (es) * 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
HUE024872T2 (en) 2008-11-22 2016-02-29 Hoffmann La Roche Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
CA2807830C (en) * 2010-08-24 2018-04-03 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
MA37850A1 (fr) 2012-08-24 2018-07-31 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
US20160206597A1 (en) * 2013-08-26 2016-07-21 Toni Lynne Bransford New Use

Also Published As

Publication number Publication date
PT3626270T (pt) 2024-01-11
DK3626270T3 (da) 2024-01-15
RS65037B1 (sr) 2024-02-29
HRP20240034T1 (hr) 2024-03-29
EP3038654A1 (en) 2016-07-06
LT3626270T (lt) 2024-01-25
HRP20200060T1 (hr) 2020-04-03
JP6097888B2 (ja) 2017-03-15
FI3626270T3 (fi) 2024-01-11
EP3626270A1 (en) 2020-03-25
HUE047186T2 (hu) 2020-04-28
EP3626270B1 (en) 2023-10-11
JP2016528303A (ja) 2016-09-15
EP3038654B1 (en) 2019-10-30
PT3038654T (pt) 2020-02-04
SI3038654T1 (sl) 2020-02-28
ES2968541T3 (es) 2024-05-10
RS59816B1 (sr) 2020-02-28
EP4321157A3 (en) 2024-05-15
DK3038654T3 (da) 2020-02-03
US20160213646A1 (en) 2016-07-28
US20210077461A1 (en) 2021-03-18
ES2767084T3 (es) 2020-06-16
EP4321157A2 (en) 2024-02-14
WO2015028941A1 (en) 2015-03-05
SI3626270T1 (sl) 2024-03-29
HUE064634T2 (hu) 2024-04-28
LT3038654T (lt) 2020-01-27
PL3038654T3 (pl) 2020-05-18
PL3626270T3 (pl) 2024-04-08

Similar Documents

Publication Publication Date Title
CY1122531T1 (el) Νεα χρηση
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
CY1120903T1 (el) Ενωσεις αμινοπυριδυλοξυπυραζολιου
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122754T1 (el) Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
CY1119577T1 (el) Συν-αγωνιστες υποδοχεα γλυκαγονης/glp-1
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1116803T1 (el) Φαρμακευτικος συνδυασμος για χρηση στον γλυκαιμικο ελεγχο σε ασθενεις με διαβητη τυπου 2
EA201490926A1 (ru) Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
CY1126036T1 (el) Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
BR112019007613A2 (pt) terapia de combinação para inibição de c3
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201600495A1 (ru) Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
CL2015000902A1 (es) Compuestos derivados de benzamidas, inhibidores del receptor 2x7 purinergico (p2x7); y composicion farmaceutica que los comprende.
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб